On Nov 28, 2023, several obesity advocacy organisations issued a joint statement calling on the US Food and Drug Administration (FDA) to stipulate that people with obesity must be included in drug trials. They also asked the FDA to mandate that any obesity-related differences in the effectiveness or safety of a drug should be detailed on its label. “Exclusion criteria routinely bar people at higher bodyweights from participating in [drug] trials”, noted the statement. “Yet it is well known drug kinetics can materially change in larger bodies…that puts people with obesity, who make up 42% of the US population, at unnecessary risk of poorer health outcomes and adverse events, including death.”

On Nov 28, 2023, several obesity advocacy organisations issued a joint statement calling on the US Food and Drug Administration (FDA) to stipulate that people with obesity must be included in drug trials. They also asked the FDA to mandate that any obesity-related differences in the effectiveness or safety of a drug should be detailed on its label. “Exclusion criteria routinely bar people at higher bodyweights from participating in [drug] trials”, noted the statement. “Yet it is well known drug kinetics can materially change in larger bodies…that puts people with obesity, who make up 42% of the US population, at unnecessary risk of poorer health outcomes and adverse events, including death.”